USPTO Examiner NATARAJAN MEERA - Art Unit 1643

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19036915ANTIBODIES THAT BIND TNFRSF25January 2025April 2025Allow300YesNo
19032739MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESJanuary 2025April 2025Allow300YesNo
19032782MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESJanuary 2025April 2025Allow300YesNo
18987178ANTI-CD161 ANTIBODIES AND USES THEREOFDecember 2024February 2025Allow200NoNo
18905034TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USEOctober 2024April 2025Allow601YesNo
18805883MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESAugust 2024December 2024Allow410NoNo
18805937MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESAugust 2024December 2024Allow410NoNo
18793279ANTIBODIES TARGETING CCR2August 2024September 2024Allow200NoNo
18656234ANTIBODIES AND ANTIBODY-DRUG CONJUGATES TARGETING CLAUDIN 6May 2024August 2024Allow300NoNo
18618626Bispecific Constructs for Target and Complement EngagementMarch 2024January 2025Allow1021YesNo
18609032MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHYMarch 2024July 2024Allow410YesNo
18590865SIRP ALPHA, SIRP BETA 1, AND SIRP GAMMA ANTIBODIES AND USES THEREOFFebruary 2024August 2024Allow610YesNo
18582950ANTI-CD161 ANTIBODIES AND USES THEREOFFebruary 2024September 2024Allow701YesNo
18495086MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYOctober 2023February 2024Allow310NoNo
18457239FUSOBACTERIUM NUCLEATUM AMYLOID-LIKE FADA FOR DIAGNOSIS AND TREATMENT OF FN-MEDIATED PATHOGENESISAugust 2023February 2024Allow600YesNo
18449190METHODAugust 2023April 2024Allow810YesNo
18330367TIM-3-TARGETING ANTIBODIES AND USES THEREOFJune 2023June 2024Allow1221YesNo
18329781MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJune 2023September 2023Allow410YesNo
18184120BINDING AGENTS BINDING TO EPCAM AND CD137March 2023April 2025Allow2541YesYes
18121975METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNAMarch 2023August 2023Allow510NoNo
18006528IL2RB BINDING MOLECULES AND METHODS OF USEJanuary 2023October 2023Allow910NoNo
18006525IL2RG BINDING MOLECULES AND METHODS OF USEJanuary 2023October 2023Allow910YesNo
18157800ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOFJanuary 2023September 2023Allow710YesNo
18092673METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNAJanuary 2023May 2023Allow400YesNo
18063797MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYDecember 2022April 2023Allow400YesNo
18063795MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYDecember 2022February 2023Allow200YesNo
18000249ANTI-NME ANTIBODY AND METHOD OF TREATING CANCER OR CANCER METASTASISNovember 2022March 2024Allow1510YesNo
17967418Multispecific Antigen-Binding Molecules for Cell Targeting and Uses ThereofOctober 2022December 2023Allow1421YesNo
18045093ANTI-TREM2 ANTIBODIES AND RELATED METHODSOctober 2022February 2025Allow2900NoNo
17934303ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAMESeptember 2022August 2023Allow1111YesNo
17930621METHODS FOR DETERMINING AND ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 AGENTS IN TREATMENT OF CANCERSeptember 2022April 2023Allow710NoNo
17819545ANTIBODIES AGAINST N-ACETYLGLUCOSAMINE AND N-ACETYL-GALACTOSAMINEAugust 2022May 2025Allow3300YesNo
17811606MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPYJuly 2022August 2024Allow2600NoNo
17811380MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJuly 2022October 2022Allow300NoNo
17859973CHIMERIC ANTIGEN RECEPTORS TARGETING GPRC5DJuly 2022December 2024Allow2910YesNo
17810377ANTI-CD38 BINDING DOMAINSJuly 2022January 2025Allow3110NoNo
17849467ANTIBODIES SPECIFIC FOR FLT3 AND THEIR USESJune 2022September 2024Allow2700NoNo
17842351ANTI-CSP ANTIBODIESJune 2022October 2022Allow400YesNo
17831245ANTI-SIRP-ALPHA ANTIBODIESJune 2022October 2022Allow410NoNo
17663396ANTI-FAP ANTIBODIES AND METHODS OF USEMay 2022January 2025Allow3210YesNo
17738588ANTI-CD47 ANTIBODIESMay 2022April 2025Abandon3510YesNo
17716830Multispecific Antigen-Binding Molecules for Cell Targeting and Uses ThereofApril 2022April 2024Allow2441YesNo
17656682AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH UNDESIRED CELL PROLIFERATIONMarch 2022January 2025Abandon3310NoNo
17695550ANTIBODIESMarch 2022December 2024Allow3310NoNo
17685029ANTI-GPRC5D MONOCLONAL ANTIBODIES AND USES THEREOFMarch 2022June 2022Allow300NoNo
17633797Therapeutic Antibodies Against OsteopontinFebruary 2022March 2025Allow3700YesNo
17580248T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULESJanuary 2022June 2024Allow2900NoNo
17570301METHODJanuary 2022December 2024Abandon3510NoNo
17562166BTLA ANTIBODIESDecember 2021December 2024Abandon3510NoNo
17550288ANTIBODIES AGAINST HUMAN CD38December 2021February 2025Allow3810NoNo
17547101ANTI-GLYCAN ANTIBODIES AND USES THEREOFDecember 2021November 2024Abandon3610NoNo
17531380Anti-CD112R Compositions and MethodsNovember 2021July 2024Allow3210NoNo
17528976HUMANIZED ANTIBODIES AGAINST C-KITNovember 2021May 2024Allow3010NoNo
17502602INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESISOctober 2021October 2023Abandon2421NoYes
17502860INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESISOctober 2021July 2023Abandon2131YesNo
17503025INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESISOctober 2021July 2023Abandon2121NoNo
17502922INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESISOctober 2021October 2023Abandon2421NoYes
17496263Readily Isolated Bispecific Antibodies with Native Immunoglobulin FormatOctober 2021July 2024Allow3410NoNo
17494545ANTIBODIESOctober 2021December 2021Allow300NoNo
17490606ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOFSeptember 2021September 2024Abandon3510YesNo
17483101METHODS AND COMPOSITIONS RELATING TO ANTI-NUCLEOLIN RECOMBINANT IMMUNOAGENTSSeptember 2021November 2024Abandon3811YesNo
17469493RECOMBINANT POLYCLONAL PROTEINS TARGETING ZIKA AND METHODS OF USE THEREOFSeptember 2021April 2023Allow1921YesNo
17402751COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND IMMUNOTHERAPYAugust 2021March 2024Abandon3110NoNo
17395400MULTISPECIFIC ANTIGEN-BINDING PROTEINSAugust 2021March 2024Allow3200YesNo
17392981ANTI-NME ANTIBODY AND METHOD OF TREATING CANCER OR CANCER METASTASISAugust 2021February 2024Allow3111YesNo
17444107ANTI-BCMA ANTIBODIESJuly 2021February 2024Abandon3010NoNo
17386397MULTIMERIC CORONAVIRUS BINDING MOLECULES AND USES THEREOFJuly 2021July 2023Abandon2440YesNo
17423426ANTIBODY AGAINST FACTOR XIA IN ACTIVATED FORM OF COAGULANT FACTOR XI, PREPARATION METHOD THEREFOR AND USE THEREOFJuly 2021October 2024Allow3900YesNo
17376319Combination Therapy of Immunotoxin and Checkpoint InhibitorJuly 2021February 2024Abandon3110NoNo
17367077RI-LABELED HUMANIZED ANTIBODYJuly 2021March 2022Allow910NoNo
17353437STEREOTYPIC NEUTRALIZING VH CLONOTYPES AGAINST SARS-COV-2 RBD IN COVID-19 PATIENTS AND THE HEALTHY POPULATIONJune 2021May 2022Abandon1110NoNo
17311307ANTI-CLAUDIN ANTIBODIES AND USES THEREOFJune 2021February 2025Abandon4501NoNo
17330168BTLA ANTIBODIESMay 2021October 2021Allow510YesNo
17295391ANTI-HER2/PD1 BISPECIFIC ANTIBODYMay 2021May 2025Allow4811NoNo
17313511ANTI-TIM-3 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-TIM-3 ANTIBODIES AND METHODS OF MAKING AND USING ANTI-TIM-3 ANTIBODIESMay 2021September 2023Abandon2810NoNo
17246771T CELL RECRUITING POLYPEPTIDES BASED ON CD3 REACTIVITYMay 2021March 2025Allow4611NoNo
17306051BISPECIFIC ANTIBODY CONSTRUCTS FOR CDH3 AND CD3May 2021October 2023Allow2910NoNo
17243362ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOFApril 2021September 2023Allow2820NoNo
17240944ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOFApril 2021January 2024Abandon3220NoNo
17229534TRANSPLANT TOLERANCE INDUCTION WITH CARBODIIMIDE TREATED TOLERIZING VACCINEApril 2021June 2025Allow5011NoNo
17229130NOVEL POLYPEPTIDESApril 2021March 2023Allow2300YesNo
17225953AN IMMUNOTOXIN FOR TREATING CANCERApril 2021March 2023Allow2310YesNo
17283229ANTI-SYNUCLEIN ANTIBODIESApril 2021September 2024Abandon4110NoNo
17221378METHODS OF PROTEIN PRODUCTIONApril 2021June 2025Allow5020YesNo
17220387CHIMERIC ANTIGEN RECEPTOR CELLS FOR TREATING SOLID TUMORApril 2021June 2021Allow300NoNo
17213588BI-SPECIFIC FUSION PROTEINS FOR DEPLETION OF REGULATORY T CELLSMarch 2021August 2024Abandon4021NoNo
17277909HUMAN PD-L1 ANTIBODIESMarch 2021August 2021Allow500NoNo
17203650ANTI-GLYCAN ANTIBODIES AND USES THEREOFMarch 2021September 2021Allow610NoNo
17187399AUTO/ALLO-IMMUNE DEFENSE RECEPTORS FOR THE SELECTIVE TARGETING OF ACTIVATED PATHOGENIC T CELLS AND NK CELLSFebruary 2021May 2025Abandon5011NoNo
17176096INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESISFebruary 2021July 2023Abandon2941NoNo
17175503INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESISFebruary 2021July 2023Allow2951YesNo
17173716ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF USEFebruary 2021March 2023Allow2510NoNo
17165760TRISPECIFIC BINDING PROTEINS AND METHODS OF USEFebruary 2021April 2024Allow3910NoNo
17261463Anti-CD112R Compositions and MethodsJanuary 2021September 2021Allow800NoNo
17133413ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOFDecember 2020March 2021Allow300YesNo
17253276ANTI-CD37 ANTIBODIES AND ANTI-CD20 ANTIBODIES, COMPOSITIONS AND METHODS OF USE THEREOFDecember 2020December 2024Allow4810NoNo
17125601METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2December 2020February 2023Allow2600NoNo
17119207METHODS OF TREATING CANCER IN SUBJECTS HAVING DYSREGULATED LYMPHATIC SYSTEMSDecember 2020July 2021Allow721YesNo
17118974TRISPECIFIC INHIBITORS FOR CANCER TREATMENTDecember 2020June 2023Abandon3001NoNo
17095102ANTIBODY AND PROTEIN FORMULATIONSNovember 2020July 2023Abandon3210NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NATARAJAN, MEERA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
6
(66.7%)
Examiner Reversed
3
(33.3%)
Reversal Percentile
48.4%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
58
Allowed After Appeal Filing
10
(17.2%)
Not Allowed After Appeal Filing
48
(82.8%)
Filing Benefit Percentile
18.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner NATARAJAN, MEERA - Prosecution Strategy Guide

Executive Summary

Examiner NATARAJAN, MEERA works in Art Unit 1643 and has examined 911 patent applications in our dataset. With an allowance rate of 64.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner NATARAJAN, MEERA's allowance rate of 64.0% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by NATARAJAN, MEERA receive 1.54 office actions before reaching final disposition. This places the examiner in the 39% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by NATARAJAN, MEERA is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +21.1% benefit to allowance rate for applications examined by NATARAJAN, MEERA. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.5% of applications are subsequently allowed. This success rate is in the 52% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 55.1% of cases where such amendments are filed. This entry rate is in the 77% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 78.0% of appeals filed. This is in the 66% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 46.7% are granted (fully or in part). This grant rate is in the 53% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.2% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.